AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Compounded Drug Products	Page:	1 of 3
Effective Date:	1/13/2025	Last Review Date:	11/26/2024
Applies to:	☒Virginia		

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for compounded drug products under the patient's prescription drug benefit.

Description:

N/A

Applicable Drug List:

N/A

Policy/Guideline:

Compounded drug products will be covered with prior authorization when the following criteria are met:

- The request is for any of the following: A) intravenous (IV) injection or infusion, B) anti-infective for injectable use (e.g., antibacterials, antivirals, antifungals), C) total parenteral nutrition (TPN), D) pyrimethamine, E) sirolimus for tuberous sclerosis where other dermatological treatments (e.g., laser therapy, surgery, dermabrasion) are inappropriate

OR

- The request is for tacrolimus (Prograf) or everolimus (Zortress) for a patient receiving a transplant

OR

- Each of the active ingredients in the compound are FDA-approved drugs
  AND
- Each of the active ingredients in the compound are FDA-approved for the indication for which the compound is being prescribed
  AND
- The compound route of administration (ROA) is the same as the FDA-approved route of administration for each active ingredient
  AND
- The dosage or concentration of each active ingredient in the compound is equal to or below the FDA-approved dosage or concentration
  AND
- The compound is not intended for anti-aging or cosmetic use, or is not a compound kit, or does not contain a bulk powder or dietary supplement
  AND
- The request is not for a hormone therapy compound for menopause or for androgen decline due to aging, (e.g., testosterone, estrogen, progestin, bioidentical hormone)
  AND

- Coverage is provided for additional fills of the compounded drug if the patient needs more than 1 fill per month (necessity may include continuation of antibiotic therapy, stability is less than a month, dose adjustment)
  AND
  - There is a current supply shortage of the commercially manufactured product
    OR
  - The patient has a medical need for a dosage form or dosage strength that is not available commercially or manufactured
    OR
  - The patient had an intolerance or contraindication to the commercially manufactured product (e.g., allergen or adverse effects due to inactive ingredients)
    OR

The commercial product has been discontinued by the pharmaceutical manufacturer for reasons other than lack of safety or effectiveness

Approval Duration and Quantity Restrictions:

Approval:

- Tacrolimus or everolimus for transplant: 12 months
- 6 months for all other approvals

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. 21 USC 353a: Pharmacy compounding From Title 21-FOOD AND DRUGS CHAPTER 9-FEDERAL FOOD, DRUG, AND COSMETIC ACT SUBCHAPTER V-DRUGS AND DEVICES Part A-Drugs and Devices. Available at: https://uscode.house.gov/view.xhtml?hl=false&edition=prelim&req=granuleid%3AUSC-prelim-title21-section353a&num=0&saved=%7CKGNvbXBvdW5kIGRydWdzKQ%3D%3D%7CdHJlZXNvcnQ%3D%7CdHJ1ZQ%3D%3D%7C15%7Ctrue%7Cprelim. Accessed July 2024.
2. Compounding Quality Act. U.S. Food and Drug Administration. Pharmacy Compounding. Available at: https://www.govinfo.gov/app/details/BILLS-113hr3204enr. Accessed July 2024.
3. Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacy-compounding-human-drug-products-under-section-503a-federal-food-drug-and-cosmetic-act. Accessed July 2024.
4. Human Drug Compounding. Available at: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding. Accessed July 2024.
5. Compounding and the FDA: Questions and Answers. Available at: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers. Accessed July 2024.
6. USP Compounding Standards. Available at: https://www.usp.org/compounding. Accessed July 2024.
7. USP Compounding Standards and Beyond-Use Dates (BUDs). Available at: https://www.mbp.ms.gov/sites/default/files/2023-03/USP_Compounding_BUD_Fact_Sheet.pdf. Accessed July 2024.

8. USP-NF Chapters on Pharmacy Compounding, 795. https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/gc795.pdf. Accessed July 2024.
9. Is it Really FDA Approved? Available at: https://www.fda.gov/forconsumers/consumerupdates/ucm047470.htm. Accessed July 2024.
10. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due. Accessed July 2024.
11. Menopause. Available at: https://www.fda.gov/consumers/womens-health-topics/menopause. Accessed July 2024.
12. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy, Jackson L.M., Parker R.M., & Mattison D.R. (Eds.). (2020) *The clinical utility of compounded bioidentical hormone therapy: A review of safety, effectiveness, and use*. National Academies Press (US).
13. Drug Information (Drugs@FDA). Available at: http://www.fda.gov/Drugs/default.htm. Accessed July 2024.
14. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com Accessed July 2024.
15. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ *(cited: 07/2024*).
16. Tuberous Sclerosis. Available at: https://rarediseases.info.nih.gov/diseases/7830/tuberous-sclerosis. Accessed July 2024.
17. Drug Nomenclature Monographs. Route of Administration. Available at: https://www.fda.gov/drugs/data-standards-manual-monographs/route-administration. Accessed July 2024.